Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
- PMID: 16437504
- DOI: 10.1002/14651858.CD004920.pub2
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Update in
-
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.Cochrane Database Syst Rev. 2016 Jan 16;2016(1):CD004920. doi: 10.1002/14651858.CD004920.pub3. Cochrane Database Syst Rev. 2016. PMID: 26772902 Free PMC article. Review.
Abstract
Background: Invasive fungal infections, important causes of morbidity and mortality in critically ill patients, may be preventable with the prophylactic administration of antifungal agents.
Objectives: This study aims to systematically identify and summarize the effects of antifungal prophylaxis in non-neutropenic critically ill adult patients on all-cause mortality and the incidence of invasive fungal infections.
Search strategy: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library, Issue 3, 2005), MEDLINE (1966 to 2 September 2005), and EMBASE (1980 to week 36, 2005). We also handsearched reference lists, abstracts of conference proceedings and scientific meetings (1998 to 2004), and contacted authors of included studies and pharmaceutical manufacturers.
Selection criteria: We included randomized controlled trials in all languages comparing the prophylactic use of any antifungal agent or regimen with placebo, no antifungal, or another antifungal agent or regimen in non-neutropenic critically ill adult patients.
Data collection and analysis: Two authors independently applied selection criteria, performed quality assessment, and extracted data using an intention-to-treat approach. We resolved differences by discussion. We synthesized data using the random effects model and expressed results as relative risk with 95% confidence intervals.
Main results: We included 12 unique trials (eight comparing fluconazole and four ketoconazole with no antifungal or a nonabsorbable agent) involving 1606 randomized patients. For both outcomes of total mortality and invasive fungal infections, almost all trials of fluconazole and ketoconazole separately showed a non-significant risk reduction with prophylaxis. When combined, fluconazole/ketoconazole reduced total mortality by about 25% (relative risk 0.76, 95% confidence interval 0.59 to 0.97) and invasive fungal infections by about 50% (relative risk 0.46, 95% confidence interval 0.31 to 0.68). We identified no significant increase in the incidence of infection or colonization with the azole-resistant fungal pathogens Candida glabrata or C. krusei, although the confidence intervals of the summary effect measures were wide. Adverse effects were not more common amongst patients receiving prophylaxis. Results across all trials were homogeneous despite considerable heterogeneity in clinical and methodological characteristics.
Authors' conclusions: Prophylaxis with fluconazole or ketoconazole in critically ill patients reduces invasive fungal infections by one half and total mortality by one quarter. Although no significant increase in azole-resistant Candida species associated with prophylaxis was demonstrated, trials were not powered to exclude such an effect. In patients at increased risk of invasive fungal infections, antifungal prophylaxis with fluconazole should be considered.
Comment in
-
[Antimycotic agent for the prevention of mycotic infections in non-neutropenic critical patients].Med Intensiva. 2006 Oct;30(7):354-8. doi: 10.1016/s0210-5691(06)74546-6. Med Intensiva. 2006. PMID: 17067512 Spanish. No abstract available.
-
Associations of Antifungal Treatments With Prevention of Fungal Infection in Critically Ill Patients Without Neutropenia.JAMA. 2017 Jan 17;317(3):311-312. doi: 10.1001/jama.2016.16535. JAMA. 2017. PMID: 28114533
Similar articles
-
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.Cochrane Database Syst Rev. 2016 Jan 16;2016(1):CD004920. doi: 10.1002/14651858.CD004920.pub3. Cochrane Database Syst Rev. 2016. PMID: 26772902 Free PMC article. Review.
-
Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials.J Antimicrob Chemother. 2006 Apr;57(4):628-38. doi: 10.1093/jac/dki491. Epub 2006 Feb 3. J Antimicrob Chemother. 2006. PMID: 16459344 Review.
-
Antifungal agents for preventing fungal infections in solid organ transplant recipients.Cochrane Database Syst Rev. 2004;(3):CD004291. doi: 10.1002/14651858.CD004291.pub2. Cochrane Database Syst Rev. 2004. PMID: 15266524 Review.
-
Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants.Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003850. doi: 10.1002/14651858.CD003850.pub3. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2013 Apr 30;(4):CD003850. doi: 10.1002/14651858.CD003850.pub4. PMID: 17943803 Updated. Review.
-
Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.Cochrane Database Syst Rev. 2010 Feb 17;2010(2):CD006343. doi: 10.1002/14651858.CD006343.pub2. Cochrane Database Syst Rev. 2010. PMID: 20166083 Free PMC article. Review.
Cited by
-
ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients.Intensive Care Med. 2019 Jun;45(6):789-805. doi: 10.1007/s00134-019-05599-w. Epub 2019 Mar 25. Intensive Care Med. 2019. PMID: 30911804
-
Antifungal Treatment Strategies in the ICU: Beyond Meta-analysis.Turk J Anaesthesiol Reanim. 2016 Dec;44(6):283-284. doi: 10.5152/TJAR.2016.0012. Epub 2016 Dec 1. Turk J Anaesthesiol Reanim. 2016. PMID: 28058137 Free PMC article. No abstract available.
-
Should we Administer Antifungal Drugs Before the Diagnosis of Invasive Fungal Infection in Non-Neutropenic Critically Ill Patients?Turk J Anaesthesiol Reanim. 2016 Dec;44(6):276-278. doi: 10.5152/TJAR.2016.0010. Epub 2016 Dec 1. Turk J Anaesthesiol Reanim. 2016. PMID: 28058135 Free PMC article. No abstract available.
-
The paradox of the evidence about invasive fungal infection prevention.Crit Care. 2016 Apr 27;20(1):114. doi: 10.1186/s13054-016-1284-7. Crit Care. 2016. PMID: 27117474 Free PMC article. No abstract available.
-
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.Cochrane Database Syst Rev. 2016 Jan 16;2016(1):CD004920. doi: 10.1002/14651858.CD004920.pub3. Cochrane Database Syst Rev. 2016. PMID: 26772902 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical